PCM
ACHL

Peregrine Capital Management’s Achilles Therapeutics ACHL Stock Holding History

Peregrine Capital Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-225,669
Closed -$2.21M – 348
2021
Q2 		$2.21M Sell
225,669
-96,592
-30% -$1.31M 0.04% 257
2021
Q1 		$5.33M Buy
+322,261
New +$5.33M 0.1% 254

Other funds holding ACHL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Peregrine Capital Management's ACHL Position: Q3 2021 in Review

Peregrine Capital Management sold out of Achilles Therapeutics (ACHL) in Q3 2021, closing a stake of 225,669 shares — an estimated $2.21M sold.

Peregrine Capital Management first reported a position in ACHL in Q1 2021 and held it in 2 quarters. The position peaked at $5.33M in Q1 2021. 20 funds tracked by Wall St. Rank hold ACHL as of Q3 2021.

  • Peregrine Capital Management reported no remaining Achilles Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 225,669 Achilles Therapeutics shares in Q3 2021, an estimated $2.21M.
  • Peregrine Capital Management first reported a position in Achilles Therapeutics in Q1 2021 and held it in 2 quarters.
  • Peregrine Capital Management's Achilles Therapeutics position peaked at $5.33M in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2021.

Based on Peregrine Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.